

AME 2021 LTC Education Symposium
Friday, September 10, 2021 * Virtual
CE Document

8:00am-9:00am

Session 1 “Examining Pharmacologic Treatment Approaches for Overactive Bladder”

Learning Objectives:

- Examine the pathophysiology, prevalence, and risk factors associated with overactive bladder (OAB) and recognize its impact on patients’ quality of life
- Explore current and new treatment options for OAB, including their efficacy and safety data
- Illustrate the role of the pharmacist in the management of OAB, including strategies for collaborating with prescribers and providing medication counseling to help improve patient outcomes

9:15am-10:15am

Session 2 “The Changing Face of Tardive Dyskinesia”

Learning Objectives:

- Describe the pathophysiology of tardive dyskinesia.
- Describe exam findings consistent with tardive dyskinesia.
- Ascertain management strategies for tardive dyskinesia.
- Incorporate strategies to educate interprofessional teams on common etiologies of tardive dyskinesia as well as common presentations, so that efforts can be made to prevent it from developing in the first place and stop it from progressing if it has already developed.

10:30am-11:30am

Session 3 “Dementia-Related Psychosis in Long-Term Care: Identification and Management”

Learning Objectives:

- Differentiate between types and causes of dementia-related psychosis (DRP).
- Compare and contrast treatments for DRP, including non-pharmacological and current pharmacological treatments.
- Examine clinical data for agents being studied for the treatment of DRP.

12:00pm-1:00pm

Session 4 “HIV/HCV Coinfection: Treatment Overview and Considerations for Antiretroviral and Direct Acting Antiviral Use”

Learning Objectives:

1. Review the epidemiology and screening recommendations for human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections
2. Identify treatment goals for HIV-infected patients and for HCV-infected patients
3. Describe the current HIV treatment guidelines and the appropriate selection of antiretrovirals when initiating therapy in antiretroviral-naive HIV-infected patients
4. Describe the current HCV treatment guidelines and the appropriate selection of treatment when initiating therapy in treatment-naive HCV-infected patients

5. Discuss how drug interactions between HIV and HCV treatments affect the care of HIV/HCV-coinfected patients

1:15-2:15pm

Session 5 “Managing Patients with COPD”

Learning Objectives:

- Identify the etiology, epidemiology, and pathophysiology of chronic obstructive pulmonary disease (COPD).
- Recall, analyze, and select appropriate history, physical, and evaluation of chronic obstructive pulmonary disease (COPD).
- Explain the treatment and management options available for chronic obstructive pulmonary disease (COPD).
- Discuss interprofessional team strategies for improving care coordination and communication to advance chronic obstructive pulmonary disease (COPD) and improve outcomes.

2:30pm-3:30pm

Session 6 Dosage Formulations

- Identify the availability of newer dosage formulation of existing drugs.
- Recall, analyze, and select appropriate dosage formulations for various patient types.
- Explain the coverage and other challenges facing treatment with expanded dosage formulations.
- Discuss interprofessional team strategies for improving care coordination and communication to advance patient care through the use of newer dosage formulations.